Scott Bessent, US Treasury Secretary, gave a statement noting that the market resilience has shown that the tariffs haven’t ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Johnson & Johnson has announced the submission of an extension of indication application to the European Medicines Agency (EMA) seeking approval of Akeega (niraparib/abiraterone acetate) with ...

Over the past four and a half years immunity to Covid-19 has increased and the disease is mild for most people. However with it still occurring regularly in Wales older people are the most vulnerable ...

Music and Chinese period dramas bring comfort to 13-year-old Er Yue Rou, who lives with the autoimmune disease. With help ...

Prednisolone acetate ophthalmic suspension 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is ...

Objective: To examine whether acute glucocorticoid (GC) intake alters performance and selected hormonal and metabolic variables during submaximal exercise. Methods: In total, 14 recreational male ...

Amneal plans to launch the product in the third quarter of 2025. According to IQVIA, U.S. annual sales for prednisolone acetate ophthalmic suspension for the 12 months ended April 2025 were about ...

Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 ...

Prednisolone acetate ophthalmic suspension, USP 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is indicated for treating steroid-responsive ocular inflammation.

Key complex product approval in the Affordable Medicines segment this year Commercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal ...